European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected ...

From my colleague Andrew Joseph: After a bumpy road, Eisai and Biogen’s Alzheimer’s therapy Leqembi has won approval in ...

Biogen BIIB and partner Eisai announced that the European Commission (EC) has granted marketing authorization to Leqembi ...

Eisai Co.’s breakthrough Alzheimer’s drug Leqembi was cleared for use in the European Union, after the medicine was approved in the US and Japan. The European Commission approved the drug to treat ...

The Trump administration is expected to announce tariffs on pharmaceuticals "in the next month or two," an official said. | ...

Eisai Co.’s breakthrough Alzheimer’s drug Leqembi was cleared for use in the European Union, after the medicine was approved ...

The European Commission said Wednesday that it had given formal approval for Leqembi, a long-awaited new treatment for ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and ...

Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi ...

Leqembi approved by the EU for early-stage Alzheimer’s in patients with specific ApoE4 gene profile, marking a milestone in ...

European regulators have approved Alzheimer's treatment Leqembi after initial rejection. The drug, from Eisai and Biogen, is ...

On Monday, 74-year-old Ralph Carmona of Portland will be the only qualified Boston Marathon runner with Alzheimer's.